XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2021
Sep. 30, 2021
Current assets:    
Cash and cash equivalents $ 2,748,368 $ 6,554,948
Accounts receivable, net of allowance of $39,821 and $29,821 at December 31, 2021 and September 30, 2021, respectively 3,857,275 2,804,039
Inventories 1,300,629 1,369,933
Prepaid expenses and other current assets 593,149 568,881
Total current assets 8,499,421 11,297,801
Property and equipment, net 2,807,852 3,023,915
Other assets:    
Deposits 95,040 95,040
Total Assets 11,402,313 14,416,756
Current liabilities:    
Accounts payable and accrued liabilities 2,521,353 2,991,343
Deferred revenue 457,538 281,000
Total current liabilities 2,978,891 3,272,343
Long term accrued liabilities 31,467 31,467
Total liabilities 3,010,358 3,303,810
Commitments and contingencies (Note F)
Applied DNA Sciences, Inc. stockholders' equity:    
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of December 31, 2021 and September 30, 2021, respectively 0 0
Common stock, par value $0.001 per share; 200,000,000 shares authorized as of December 31, 2021 and September 30, 2021, 7,486,120 shares issued and outstanding as of December 31, 2021 and September 30, 2021 7,488 7,488
Additional paid in capital 297,228,192 295,228,272
Accumulated deficit (288,843,858) (284,122,092)
Applied DNA Sciences, Inc. stockholders' equity: 8,391,822 11,113,668
Noncontrolling interest 133 (722)
Total equity 8,391,955 11,112,946
Total liabilities and equity 11,402,313 14,416,756
Series A Preferred Stock [Member]    
Applied DNA Sciences, Inc. stockholders' equity:    
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of December 31, 2021 and September 30, 2021, respectively 0 0
Series B Preferred Stock [Member]    
Applied DNA Sciences, Inc. stockholders' equity:    
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of December 31, 2021 and September 30, 2021, respectively $ 0 $ 0